Home/Pipeline/NaviFUS for Drug‑Resistant Epilepsy

NaviFUS for Drug‑Resistant Epilepsy

Epilepsy

Phase 1Active

Key Facts

Indication

Epilepsy

Phase

Phase 1

Status

Active

Company

A Taiwanese biotech leveraging non‑invasive focused ultrasound to breach the BBB for targeted CNS drug delivery.

Drug	Company	Phase	Status
ADX71149 (mGlu2 PAM)	Addex Therapeutics	Phase 2	Active (with Janssen)
TRV045	Trevena	Phase 1	Active
SAGE-324	Sage Therapeutics	Preclinical	Research
Motpoly XR™	Aucta Pharmaceuticals	Not Specified (Likely Phase 3/NDA)	Active
ADB-104	Adolore BioTherapeutics	Pre-clinical	Active
Not Publicly Disclosed	Cerecin	Phase 2	Active
eTNS Platform	NeuroSigma	Unknown	Active
NPT 2042	NeuroPro Therapeutics	Phase 2	Active
Spritam (levetiracetam)	Aprecia Pharmaceuticals	Approved	Active
Perampanel	Ark Diagnostics	In Development	Active
NeuroAccess Platform	Cordance Medical	Pre-clinical/Research	Active
Epilepsy Program	Current Surgical	Research	Active